Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C. Hartung HP, et al. Among authors: stemper b. J Neurol. 2015 Nov;262(11):2466-71. doi: 10.1007/s00415-015-7862-9. Epub 2015 Aug 5. J Neurol. 2015. PMID: 26239222 Free PMC article.
Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies.
Hartung HP, Kieseier B, Goodin DS, Arnason BG, Comi G, Cook S, Filippi M, Jeffery DR, Kappos L, Bogumil T, Stemper B, Sandbrink R, Nakada Y, Nakajima H, Schwenke S, Lehr S, Heubach J, Pohl C, Reischl J. Hartung HP, et al. Among authors: stemper b. J Neuroinflammation. 2012 Jun 15;9:129. doi: 10.1186/1742-2094-9-129. J Neuroinflammation. 2012. PMID: 22703536 Free PMC article. Clinical Trial.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D; BENEFIT Study Group. Edan G, et al. Among authors: stemper b. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9. doi: 10.1136/jnnp-2013-306222. Epub 2013 Nov 11. J Neurol Neurosurg Psychiatry. 2014. PMID: 24218527 Free PMC article. Clinical Trial.
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.
Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Pleimes D, Lanius V, Pohl C, Kappos L, Sandbrink R. Penner IK, et al. Among authors: stemper b. Mult Scler. 2012 Oct;18(10):1466-71. doi: 10.1177/1352458512442438. Epub 2012 Apr 4. Mult Scler. 2012. PMID: 22492127 Free PMC article. Clinical Trial.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D, Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH, Sandbrink R, Barkhof F. Nagtegaal GJ, et al. Among authors: stemper b. Mult Scler. 2014 Feb;20(2):234-42. doi: 10.1177/1352458513494491. Epub 2013 Jul 10. Mult Scler. 2014. PMID: 23842212 Clinical Trial.
Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.
Acaster S, Swinburn P, Wang C, Stemper B, Beckmann K, Knappertz V, Pohl C, Sandbrink R, Gondek K, Edan G, Kappos L, Freedman M, Hartung HP, Arnason B, Comi G, Filippi M, Jeffery D, O'Connor P, Cook S, Lloyd AJ. Acaster S, et al. Among authors: stemper b. Mult Scler. 2011 Dec;17(12):1504-13. doi: 10.1177/1352458511414039. Epub 2011 Jul 14. Mult Scler. 2011. PMID: 21757536
The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial.
Joussen AM, Wolf S, Kaiser PK, Boyer D, Schmelter T, Sandbrink R, Zeitz O, Deeg G, Richter A, Zimmermann T, Hoechel J, Buetehorn U, Schmitt W, Stemper B, Boettger MK. Joussen AM, et al. Among authors: stemper b. Br J Clin Pharmacol. 2019 Feb;85(2):347-355. doi: 10.1111/bcp.13794. Epub 2018 Nov 25. Br J Clin Pharmacol. 2019. PMID: 30341774 Free PMC article. Clinical Trial.
Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group. Ogura Y, et al. Among authors: stemper b. Am J Ophthalmol. 2014 Nov;158(5):1032-8. doi: 10.1016/j.ajo.2014.07.027. Epub 2014 Jul 25. Am J Ophthalmol. 2014. PMID: 25068637 Clinical Trial.
Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group. Korobelnik JF, et al. Among authors: stemper b. Ophthalmology. 2014 Jan;121(1):202-208. doi: 10.1016/j.ophtha.2013.08.012. Epub 2013 Sep 29. Ophthalmology. 2014. PMID: 24084497 Free article. Clinical Trial.
177 results